ROMA Index (CA-125 + HE4)

In modern medicine, one of the important methods of detecting and diagnosing tumors is the use of tumor markers. These specific biomarkers allow doctors not only to detect tumor processes in time, but also to determine their type, stage and determine the effectiveness of treatment. One of such tumor markers is CA-125, as well as HE4. When these two indicators are combined into a single ROMA index, they become even more informative for diagnosing tumors.

CA-125, or serum-like antigen 125, is a glycoprotein produced by various ovarian cells. It is normally present in low concentrations in the blood of women, but its levels can increase if an ovarian tumor develops. Therefore, CA-125 is often used as a biomarker for the detection and monitoring of ovarian cancer.

HE4, or human epithelial antigen 4, is another biomarker used to diagnose ovarian and endometrial tumors. It can also be elevated in the blood of women with ovarian cancer and other reproductive disorders.

The ROMA (Risk of Ovarian Malignancy Algorithm) index is an algorithm that combines information about the levels of CA-125 and HE4 in the blood, as well as the age of the woman. It is designed to more accurately diagnose the risk of developing ovarian cancer. Studies have shown that the combination of these two biomarkers and age can help separate patients at low risk from those with suspected ovarian cancer.

The ROMA index works by calculating the probability of ovarian cancer based on the levels of CA-125 and HE4 in a patient's blood. This index can be useful for doctors in determining the strategy of examination and treatment, as well as in making decisions about surgical interventions.

It is important to remember that the ROMA index is not an absolute diagnostic sign of ovarian cancer, and its results should be considered together with other clinical and imaging methods of research. It is also worth noting that elevated levels of CA-125 and HE4 can be observed in other diseases not related to ovarian cancer, therefore additional diagnostics and consultation of a specialist are mandatory.

In summary, the ROMA index (CA-125 + HE4) is a useful tool in the diagnosis of ovarian tumors, especially in cases where their development is suspected. It helps doctors to obtain more accurate information about the risk and helps to determine further tactics of examination and treatment of patients. However, the diagnosis of cancer should always be confirmed by other methods of examination, and treatment should be prescribed in accordance with all clinical indicators and examination results.